Mutations in β-A-mannosidase (MANBA) (OMIM: 248510) and galactosylceramidase (GALC) (OMIM: 245200) lead to lysosomal storage disorders with neurological symptoms or myelination problems, and anti-galactosyl ceramide antibodies are specific for MS [66] (Table 2). Here, GALC is linked to myeloid sarcoma.